Skip to main content
NIH funding notice PAR-19-305

Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional)

Closed on July 16, 2022.

Posted
June 25, 2019
Close date
July 16, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

7 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,661,704 in first-year total cost, median $241,500.

Most frequent study sections

  1. Aging Systems and Geriatrics Study Section[ASG]3
  2. Cellular Mechanisms in Aging and Development Study Section[CMAD]1
  3. Neural Oxidative Metabolism and Death Study Section[NOMD]1
  4. Special Emphasis Panel[ZRG1 CB-F (02)]1
  5. Special Emphasis Panel[ZRG1 IFCN-J (02)]1

Most frequent institutions

  1. MASSACHUSETTS GENERAL HOSPITAL1
  2. SCRIPPS FLORIDA1
  3. UNIVERSITY OF CONNECTICUT STORRS1
  4. UNIVERSITY OF MICHIGAN AT ANN ARBOR1
  5. UNIVERSITY OF SOUTH FLORIDA1
Competing awards under PAR-19-305 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Protease Resistant Growth Factor Nanoparticles for Chronic Wound Healing1R21AG077426-01A1KORIA, PIYUSHUNIVERSITY OF SOUTH FLORIDA, FL$190,850ASG
2022Toward Precision Gene Therapy for Treatment of Severe Pain in Older Individuals1R21AG075419-01WAINGER, BRIAN JASONMASSACHUSETTS GENERAL HOSPITAL, MA$248,632ZRG1
2022Targeting the longevity regulator PAPP-A with small molecule inhibitors1R21AG077856-01LOMBARD, DAVID BENNERNIKOLOVSKA-COLESKA, ZANETAUNIVERSITY OF MICHIGAN AT ANN ARBOR, MI$237,891ZRG1
2022Improving healthspan through discovery of potent NAMPT activators from a DNA-encoded library1R21AG074498-01A1DONATO, ANTHONY JOHNFRANZINI, RAPHAEL M.UNIVERSITY OF UTAH, UT$205,806CMAD
2021Metformin Therapy for Ischemic Insult and Reperfusion Injury in Aging1R21AG071249-01A1LESNEFSKY, EDWARD JLI, JI N,VIRGINIA COMMONWEALTH UNIVERSITY, VA$242,375ASG
2021Treating T cell immunodeficiency among older adults by a recombinant Foxn1 fusion protein1R21AG072234-01LAI, LAIJUNUNIVERSITY OF CONNECTICUT STORRS, CT$241,500ASG
2020Mitochondrial therapeutics for healthy brain aging1R21AG068887-01DAVIS, RONALD LSCRIPPS FLORIDA, FL$294,650NOMD

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-19-305: Early-Stage T1 Translational Aging Research (Bench to Bedside) for the Development of Novel Therapeutics (R21/R33 Clinical Trial Optional) | ScienceDex | ConductScience